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Background
The treatment of unprovoked venous thromboembolism
(VTE) is anticoagulant therapy for at least 3 months [1]. As
VTE recurs frequently and about 20 % of the patients with
an unprovoked VTE develop recurrence within the first
2 years [2], extended vitamin K antagonist (VKA) treat-
ment is often considered. The decision to prolong VKA
therapy after the initial treatment period is a dilemma, since
longer term therapy reduces the risk of recurrent throm-
boembolism, but increases the risk of bleeding. The last
American College of Chest Physicians (ACCP) Evidence-
Based Clinical guidelines suggest a strategy to balance the
benefits and risks of different durations of anticoagulant
therapy; in unprovoked VTE, ACCP guidelines suggest
extended anticoagulant therapy if bleeding risk is low or
moderate (Grade 2B) and recommend 3 months of therapy
if bleeding risk is high. When extended anticoagulant
therapy is contraindicated, aspirin might be appealing. In
fact the annual risk of major bleeding is only 0.1 % in
patients on long-term low-dose aspirin therapy, thus lower
than VKA therapy [3]. A large meta-analysis by the
Antiplatelet Trialists’ Collaboration shows that antiplatelet
therapy significantly reduces the risk of fatal or non-fatal
pulmonary embolism (PE) by 25 % [3]. Moreover, a large
trial involving patients undergoing surgery for hip fracture
shows a 36 % risk reduction in VTE in the aspirin therapy
group, [4] suggesting that antiplatelet therapy may be an
alternative to prolonged VKA therapy.
Two randomized controlled studies were conducted to
evaluate the use of ASA for the prevention of venous
thromboembolism recurrence: the Aspirin for the Preven-
tion of Recurrent Venous Thromboembolism (Warfarin
and Aspirin [WARFASA]) [5] and the Aspirin to Prevent
Recurrent Venous Thromboembolism (ASPIRE) study [6].
WARFASA
Summary
The Aspirin for the Prevention of Recurrent Venous
Thromboembolism (VTE) (Warfarin and Aspirin [WAR-
FASA]) [5] is a multicentre, randomized, double-blind,
event-driven clinical trial, assessing the benefit of aspirin in
the secondary prevention of venous thromboembolic events
after the discontinuation of VKA therapy. Patients were
considered eligible if they were diagnosed with a first-ever,
unprovoked (defined by the absence of any known risk factor
for this event), symptomatic and instrumentally confirmed
proximal deep-vein thrombosis or pulmonary embolism and
if they were treated with vitamin K antagonists for
6–18 months. Most important exclusion criteria were known
cancer, known major thrombophilia, active bleeding or high
risk for bleeding or a bleeding episode, which occurred
during the 6–18 months of anticoagulation. The primary
outcome was the recurrence of VTE, defined as deep-vein
thrombosis or pulmonary embolism. The principal safety
concern outcome was major bleeding. The secondary out-
comes included arterial ischemic events (myocardial
infarction, unstable angina, stroke, transient ischemic attack,
acute limb ischemia) and death from any cause.
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The primary efficacy analysis, which considered all
outcome events occurring from randomization to the end of
the study, was performed according to a modified inten-
tion-to-treat principle, with all patients who received at
least one dose of the assigned study drug after randomi-
zation included in the analysis; an ‘‘on-treatment’’ analysis
was also performed. During the study the protocol was
modified: the primary outcome changed from a composite
endpoint in which venous and arterial events and deaths
were considered, to a simple endpoint (venous thrombo-
embolism only).
A total of 403 patients were included; of these patients
205 were randomly assigned to aspirin 100 mg/day and
198 to placebo for 2 years of therapy. The primary out-
come occurred in 5.9 and 11.0 % patients year in the
aspirin and placebo group, respectively, corresponding to
an Hazard Ratio of 0.58 (95 % CI 0.36–0.93). A multi-
variate analysis adjusted for age, sex, index event (deep-
vein thrombosis or pulmonary embolism) and length of
anticoagulant therapy confirmed the efficacy of aspirin.
Two episodes of major bleeding occurred, one in each
study group. There were no significant differences between
the two groups in the secondary outcomes.
Strengths of the study
• It addresses a relevant clinical issue. Epidemiological
evidence shows that aspirin reduces the incidence of
symptomatic pulmonary embolism (PE) in subjects
with or without previous episodes of VTE. There is no
evidence to support a role for aspirin in the secondary
prevention of VTE.
• The primary endpoint is clinically relevant.
• Two years are an appropriate follow-up period to
evaluate thromboembolic events.
Weaknesses of the study
• The primary endpoint was changed during the study
period, exposing the trial to the risk of bias.
Question marks
• Patients with cancer were excluded from the trial,
however, four patients died from cancer and it is not
specified the number of patients with a new cancer
diagnosis during the study period. It would be inter-
esting to have more data on these oncologic patients.
• Few patient characteristics were reported in Table 1.
Considering also that recent guidelines [1] suggest a
strategy that considers both thrombotic and hemor-
rhagic risk factors of individual patients to decide on
the duration of anticoagulant therapy, we wonder if
more data on patients could help in the understanding
of which patients are likely to benefit most from aspirin
therapy.
Sponsorship
It is an independent study; Bayer provided aspirin and
placebo but had no other role in the study.
ASPIRE
Summary
The Aspirin to Prevent Recurrent Venous Thromboembo-
lism (ASPIRE) study [6] was a double-blind, randomized,
placebo-controlled study, evaluating the use of low-dose
aspirin in preventing the recurrences of venous thrombo-
embolism, in patients who had had a first episode of
unprovoked venous thromboembolism and who had com-
pleted initial anticoagulation therapy.
Patients included were at least 18 years of age and had
had a first unprovoked (i.e. in the absence of a predefined
transient risk factor during the preceding 2 months) epi-
sode of objectively diagnosed symptomatic deep-vein
thrombosis or an acute pulmonary embolism occurred
within 2 years before enrollment. All patients were
required to have completed initial anticoagulation therapy
with heparin followed by warfarin (or an alternative anti-
coagulant) for a period between 6 weeks and 24 months.
The main exclusion criteria were indications/contra-
indications for aspirin use, other antiplatelet therapy, or
nonsteroidal anti-inflammatory drug, indications for
continuing oral anticoagulation therapy, active bleeding or
high risk for bleeding, life expectancy less than 12 months.
The primary outcome was the recurrence of VTE, defined
as deep-vein thrombosis or pulmonary embolism. The two
secondary composite outcomes were major vascular events
(myocardial infarction, stroke, venous thromboembolism,
or cardiovascular death) and the measure of the net clinical
benefit (defined as a reduction in the rate of the myocardial
infarction, stroke, venous thromboembolism, major bleed-
ing, or death from any cause). The primary safety outcome
was bleeding (major bleeding or clinically relevant non-
major bleeding).
The ASPIRE study was originally designed to recruit
3,000 patients, but the target sample size was then reduced
to 1,500 patients because of slow recruitment. The authors
planned to combine the final results of the study with those
of the WARFASA trial [5], in a meta-analysis, with interim
trial results concealed. Recruitment closed in August 2011
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because of limited resources and the study was stopped on
31 March 2012, after publication of the results of the
WARFASA study [5], since the ASPIRE results could be
influenced if some patients switched to aspirin on the basis
of the results of the WARFASA.
The analysis for primary and secondary outcomes was
performed according to an intention-to-treat model.
Additional analyses were performed with adjustment for
non adherence rate (the proportion of patients assigned to
aspirin who discontinued it and the proportion of patients
assigned to placebo who initiated antiplatelet or antico-
agulation) and interactions in Cox models were used to
assess differences in the effect of aspirin across pre-
specified subgroups (according to age, gender, duration of
initial anticoagulation therapy, BMI, and type of first
unprovoked event). A final meta-analysis was performed
with the combined results of the ASPIRE and WAR-
FASA [5] trials.
A total of 822 patients were randomly assigned to
receive aspirin 100 mg/day or matching placebo, for a
minimum of 2 years; the maximum duration of treatment
was 4 years. The median of follow-up was 37.2 months.
No significant differences emerged between the two groups
for the primary outcome, since VTE recurred in 73 of 411
patients assigned to placebo and in 57 of 411 assigned to
aspirin (hazard ratio [HR] with aspirin, 0.74; 95 % confi-
dence interval [CI], 0.52–1.05; P = 0.09). The analysis in
subgroups was also non-significant for the primary
outcome.
Aspirin reduced the rate of the two secondary composite
outcomes: the rate of major vascular events was reduced by
34 % (8.0 % per year with placebo vs. 5.2 % per year with
aspirin; HR with aspirin, 0.66; 95 % CI, 0.48–0.92;
P = 0.01) and the net clinical benefit (reduction in the rate
of the myocardial infarction, stroke, venous thromboem-
bolism, major bleeding, or death from any cause) was 33 %
in aspirin group, with an event rate of 9 % per year in the
placebo group and 6 % per year in aspirin group (hazard
ratio with aspirin, 0.67; 95 % CI, 0.49–0.91; P = 0.01).
There were no significant differences between the two
groups in the safety outcome (a rate of 0.6 % events per
year in the placebo group and 1.1 % in the aspirin group,
P = 0.22).
The final meta-analysis, in which results from WAR-
FASA and ASPIRE trial were combined, showed that
aspirin significantly reduces the primary outcome (hazard
ratio [HR] with aspirin, 0.68; 95 % confidence interval
[CI], 0.51–0.90; P = 0.007); a reduction of the secondary
outcome (major vascular event) is also confirmed (hazard
ratio [HR] with aspirin, 0.66; 95 % confidence interval
[CI], 0.51–0.86; P = 0.002) without increasing bleedings
(hazard ratio [HR] with aspirin, 1.47; 95 % confidence
interval [CI], 0.70–3.08; P = 0.31).
Strengths of the study
• This is a well-designed study that addresses a relevant
clinical issue, supported by a valid rationale.
• The primary endpoint is well defined and has a high
clinical relevance; the follow-up period is adequate to
evaluate VTE recurrences.
Weaknesses of the study
• The number of patients enrolled is severely lower than
the sample size originally designed by the study
protocol.
• The study is affected by a 22 % combined rate of non-
adherence to the study drug (15 % patients in the
aspirin group discontinued the study drug and 7 % in
the placebo group initiated antiplatelet or anticoagulant
treatment). Although the primary analysis has been
done according to the intention-to-treat principle, we
think that the high non-adherence rate might cause a
bias in the study results.
Question marks
• About 25 % patients in both groups had completed
anticoagulant therapy for a period between 1 month and
2 years before randomization: it would be interesting to
know if there is a difference in the average duration of
this period between one group and the other.
• It is not clear how the protocols of the ASPIRE and
WARFASA trials were prospectively harmonized to
combine the results of the studies. We wonder if in the
course of study any protocol changes were made, which
could expose the study to a possible risk of bias.
• Patients with cancer do not meet the inclusion criteria,
because they have an indication to anticoagulant
therapy (with the exception of subjects at elevated risk
of bleeding which is an exclusion criterion). We
wonder why these patients were enrolled in the study.
Sponsorship
It is an independent study; Bayer provided aspirin and
placebo but had no other role in the study.
Clinical bottom line of the two studies
In subjects with contraindications to assume anticoagulant
therapy for more than 6 months, aspirin could be a valid
therapeutic option for the prevention of venous thrombo-
embolism recurrence.
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